

September 21, 2017  
 Symbio Pharmaceuticals Limited  
 Fuminori Yoshida  
 Representative Director  
 President and Chief Executive Officer  
 (Securities Code: 4582)

### Notice of Revision to the Earnings Forecast for FY2017

TOKYO, Japan, September 21, 2017 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo) today announced a revision to its earnings forecast for the fiscal year 2017 previously disclosed on February 9, 2017, to reflect its current business performance.

#### (1) Earnings Forecast for Fiscal Year 2017 (January 1, 2017 to December 31, 2017)

	Net Sales	Operating Profit	Ordinary Profit	Net Profit	Net Profit per Share
	In millions of yen	In millions of yen	In millions of yen	In millions of yen	In yen
Previous Forecast (A)	2,903	(3,238)	(3,303)	(3,306)	(71.07)
Revised Forecast (B)	3,583	(3,932)	(4,009)	(4,009)	(82.16)
Increase/Decrease (B-A)	680	(693)	(706)	(702)	—
Percentage Change (%)	23.4	—	—	—	—
(Reference) The previous fiscal year ended December 31, 2016	2,368	(2,127)	(2,316)	(2,313)	(58.82)

#### (2) Rationale for the Revision

The sales forecast for the fiscal year 2017 is expected to be 3,583 million yen, 680 million yen higher than the previous forecast, primarily due to the significantly stronger in-market performance of TREAKISYM® than planned, following approval for the new indication of first-line treatment of low-grade non-Hodgkin's lymphoma and mantle cell lymphoma in December 2016.

The operating profit, the ordinary profit and the net profit are forecasted to be lower than the previous forecast due to the upfront payment relating to the license agreement with Eagle Pharmaceuticals, Inc. for the liquid formulation products of Bendamustine Hydrochloride, while the selling, general and administrative expenses have been solidly managed within the original budget on an ongoing-business basis.

Details on the above license agreement are stated in the press release "Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to Symbio Pharmaceuticals Limited" dated September 21, 2017.

\*Any forward-looking statements in this press release, including the forecast of financial results, are estimates based on information available at the relevant time and certain assumptions that Symbio's management believes to be reasonable. Actual results may differ substantially from such forecasts due to various factors.

#### [Contact]

Investor Relations

Tel: +81(0)3 5472 1125